Spyglass Pharma (NASDAQ:SGP) Director Buys $59,040,000.00 in Stock

Spyglass Pharma, Inc. (NASDAQ:SGP) Director Ra Capital Management, L.P. bought 3,690,000 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were purchased at an average cost of $16.00 per share, with a total value of $59,040,000.00. Following the purchase, the director directly owned 5,966,439 shares of the company’s stock, valued at approximately $95,463,024. This represents a 162.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Spyglass Pharma Stock Performance

About Spyglass Pharma

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).